Get Preprint By Doi is an example object payload from medRxiv, with 4 top-level fields. It illustrates the shape of data this provider's APIs accept or return.
{
"title": "Get medRxiv Preprint by DOI",
"description": "Retrieve all versions of a specific preprint using its DOI. Returns metadata for each version that has been posted.",
"request": {
"method": "GET",
"url": "https://api.medrxiv.org/details/medrxiv/10.1101/2021.04.29.21256344/na/json",
"parameters": {
"server": "medrxiv",
"doi": "10.1101/2021.04.29.21256344",
"format": "json"
}
},
"response": {
"status": 200,
"body": {
"messages": [
{
"status": "ok",
"interval": "10.1101/2021.04.29.21256344",
"cursor": "0",
"count": 2,
"count_new_papers": 1,
"total": 2
}
],
"collection": [
{
"doi": "10.1101/2021.04.29.21256344",
"title": "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months",
"authors": "Thomas, SJ; Moreira, ED; Kitchin, N; Absalon, J; Gurtman, A; Lockhart, S; Perez, JL; Pérez Marc, G; Polack, FP; Zerbini, C; Bailey, R; Swanson, KA; Xu, X; Roychoudhury, S; Koury, K; Chakraborty, S; Seamons, OP; Xie, P; Shi, M; Yang, X; Absalon, J",
"author_corresponding": "Thomas, SJ",
"author_corresponding_institution": "Pfizer Inc",
"date": "2021-04-30",
"version": "1",
"type": "new result",
"license": "cc_by_nc_nd",
"category": "infectious diseases",
"jatsxml": "https://www.medrxiv.org/content/early/2021/04/30/2021.04.29.21256344.source.xml",
"abstract": "Background: The BNT162b2 mRNA Covid-19 vaccine was found to be safe and 95% effective against Covid-19 through up to 2 months after the second dose.",
"published": "10.1056/NEJMoa2110345",
"server": "medrxiv"
},
{
"doi": "10.1101/2021.04.29.21256344",
"title": "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months",
"authors": "Thomas, SJ; Moreira, ED; Kitchin, N; Absalon, J; Gurtman, A; Lockhart, S; Perez, JL; Pérez Marc, G; Polack, FP; Zerbini, C; Bailey, R; Swanson, KA; Xu, X; Roychoudhury, S; Koury, K; Chakraborty, S; Seamons, OP; Xie, P; Shi, M; Yang, X",
"author_corresponding": "Thomas, SJ",
"author_corresponding_institution": "Pfizer Inc",
"date": "2021-09-08",
"version": "2",
"type": "confirmatory result",
"license": "cc_by_nc_nd",
"category": "infectious diseases",
"jatsxml": "https://www.medrxiv.org/content/early/2021/09/08/2021.04.29.21256344.source.xml",
"abstract": "Background: Randomized controlled trials have demonstrated vaccine safety and high efficacy against Covid-19. We report safety and efficacy of BNT162b2 through up to 6 months of follow-up.",
"published": "10.1056/NEJMoa2110345",
"server": "medrxiv"
}
]
}
}
}